4 news items
Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
VKTX
4 Jun 24
population, defined as all patients who were randomized and received at least one dose of study drug. 1) Deemed by investigator
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
ALT
AMGN
GS
17 May 24
of its obesity drug,VK2735, in early-stage and mid-stage studies, respectively. This investigational drug has blockbuster potential, having
Should You Hold Viking Therapeutics in Your Portfolio?
AMGN
LLY
NVO
15 May 24
.
The investigational drug is expected to reflect blockbuster potential, having demonstrated superior weight reduction capabilities in both clinical studies, coupled
Viking Therapeutics' Investigational Oral Obesity Drug Shows Reduced Weight In Small Study
VKTX
26 Mar 24
- Prev
- 1
- Next